Medtronic is supporting a public health campaign — led by the American Heart Association and the American Stroke Association — urging the public to seek emergency care when they need it. See what else we're doing in the fight against COVID-19.Visit the Resource Center
Evolut™ TAVR Best Practices
The cusp overlap technique brings precision and control to the TAVR procedure by isolating the non-coronary cusp, providing an accurate anatomical view to access and achieve the target implant depth. In combination with slow deployment starting at the supra-annular level, the valve is able to descend to its target position with minimal catheter manipulation, minimizing the risk of interaction with the conduction system.
Resolute Onyx™ DES
Evidence counts when it comes to short DAPT decisions. The Onyx ONE Clear Analysis evaluated over 1,500 complex high bleeding risk (HBR) patients, which led Resolute Onyx to become the only drug-eluting stent approved for HBR patients and labeled for 1-month DAPT.1
Endurant™ AAA Stent Graft demonstrates consistent and high sac regression rates across straightforward and complex anatomies.2,3 With:
IN.PACT Admiral drug-coated balloon is supported by 5-year data from an IDE and real-world global study.5
The Evolut TAV's supra-annular, self-expanding valve design delivers exceptional hemodynamics and is the only TAVR device to demonstrate hemodynamic superiority in a low risk clinical trial vs. SAVR at one year.7
Designed to determine the safety and efficacy of renal denervation (RDN) in the presence of up to three standard antihypertensive medications. Learn more at clinicaltrials.gov.
Patients treated with IN.PACT AV DCB show reduced need for reinterventions compared to PTA.6
Read the Circulation: Cardiovascular Interventions article, evaluating Resolute Onyx DES in ~1,500 highly complex HBR patients on 1-month DAPT.
Designed to evaluate if a targeted procedural approach in the distal main and first order branches provides similar BP reductions as those observed in the SPYRAL HTN-OFF MED Pivotal Trial. Learn more at clinicaltrials.gov.
Contact us to learn more and discuss patient eligibility requirements for SPYRAL HTN-ON MED or SPYRAL DYSTAL trials.
*CAUTION: Investigational device. Limited by federal (U.S.) law to investigational use.
Watch as subject matter experts review case studies and discuss the most recent clinical evidence, as well as decision making for the most complex HBR patients, like those studied in the Onyx ONE Month DAPT Program.
Access interactive global webcasts delivered by industry-leading experts on a wide range of relevant topics related to transcatheter aortic valve replacement.
Earn CEU credits while learning about different elements of CTO, including pathology, risks and benefits in treating CTO lesions, and treatment progression in cardiac catheterization procedures.
Preview the latest on-demand education for physicians, fellows, cath lab staff, and hospital administrators, designed to support individual coronary programs.
As your partner in the evolving healthcare landscape, we've developed various webinar series for real-time and on-demand learning with peer-to-peer discussion.
Resolute Onyx DES IFU
Bӧckler D, Li C, Dansey K, et al. Sac regression is associated with lower all-cause mortality after contemporary endovascular aneurysm repair — a new paradigm for success. Presented online at ESVS 34th Annual Meeting, October 6, 2020.
Medtronic data on file.
Wakefield TW, Shulkin BL, Fellows EP, Petry NA, Spaulding SA, Stanley JC. Platelet reactivity in human aortic grafts: a prospective, randomized midterm study of platelet adherence and release products in Dacron and polytetrafluoroethylene conduits. J Vasc Surg. February 1989;9(2):234-243.
IN.PACT Global Study 5-year Outcomes Full Clinical Cohort, Zeller, T. VIVA 2020.
Lookstein RA, et al. Drug-Coated Balloons for Dysfunctional Dialysis Arteriovenous Fistulas. N Engl J Med. 2020;383:733-42. DOI: 10.1056/NEJMoa1914617. Highlighted results reported at both 180 and 210 days.
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. May 2, 2019;380(18):1706-1715.